What is it?
What it is
1Resveratrol is a stilbene polyphenol found in grapes, berries, peanuts, Japanese knotweed, and other plants. Supplements usually emphasize trans-resveratrol, the better-defined form used in many human studies, but source, purity, and formulation can vary widely.
Names, aliases and forms
Potential effects and evidence map
Human resveratrol research includes acute cerebral blood-flow studies, postmenopausal-women trials, and cognition meta-analyses. The best read is limited and mixed: selected memory or cerebrovascular markers may move in some populations, but same-day focus, broad mood, disease-risk, and longevity claims are not established. Oral bioavailability is a central limitation for comparing products.
Resveratrol has limited human evidence for select memory outcomes, mostly in adult or older-adult study contexts.
In one small acute trial, resveratrol changed cerebral blood-flow variables without improving cognitive performance.
Human outcomes relevant to long-term brain support are limited, population-specific, and not established for healthy adults.
Mood findings are small and inconsistent rather than a reliable mood-support effect.
Typical dosages and timing
A 14-week trial in postmenopausal women used 75 mg trans-resveratrol twice daily. This describes that study context, not a universal target for every product or person.
A 28-day trial in healthy young adults used 500 mg trans-resveratrol daily with piperine. It reported a task-specific cognitive result, not a broad brain-performance benefit. This is study context, not a universal target.
In a small healthy-adult crossover trial, 250 mg and 500 mg single doses changed cerebral blood-flow variables without changing cognitive performance.
The postmenopausal trial used repeated intake for 14 weeks. Study duration is not an evidence-backed cycle protocol.
Timing & effect horizon
In the healthy-adult trial, testing followed a 45-minute resting absorption period. The study found changes in cerebral blood-flow variables, not a predictable focus effect.
A 24-month crossover study in postmenopausal women used 75 mg trans-resveratrol twice daily in 12-month treatment periods. This is research duration, not cycle advice.
Safety, side effects and risk profile
A 29-day healthy-volunteer trial found mild-to-moderate GI symptoms at 2.5-5 g/day; those doses are far above the chronic study contexts summarized here.
Optimal dose, long-term effects, and medication-interaction questions still need better trials.
At 1 g/day for four weeks, a healthy-volunteer study changed CYP phenotypic measures. This does not establish a clinical interaction at lower supplemental amounts, but medication compatibility should not be assumed.
Postmenopausal-women studies do not establish pregnancy or lactation safety.
In the United States, dietary-supplement structure/function claims are not pre-approved by FDA and must be truthful and not misleading; this is claim context, not an ingredient-specific legality restriction.
A small 90-day pilot in overweight adults aged 65+ compared 300 mg/day with 1,000 mg/day. The 1,000 mg/day group had higher cardiovascular-risk biomarkers; this does not show the same effect at lower supplemental amounts.
Interactions and cautions
In healthy volunteers taking 1 g/day for four weeks, resveratrol changed CYP phenotypic measures. This does not prove a clinical interaction at lower supplemental amounts, but medication compatibility should not be assumed.
Legal and regulatory status
As of 2026, U.S. dietary-supplement structure/function claims are not pre-approved by FDA. Marketers must have substantiation that claims are truthful and not misleading and must avoid disease claims.
How it compares
Trials differ by age, metabolic context, sex, formulation, dose, absorption window, and outcome measure. Acute studies often track blood-flow markers, while chronic studies may run for weeks or months and measure selected cognitive domains. That makes the population and product form central to interpreting claims.
Practical buying and quality notes
- Compare stated trans-resveratrol milligrams, source such as Japanese knotweed or grape, percent standardization, capsule count, COA/testing, serving size, and price per 100 mg. View piperine or liposomal delivery as label claims, not proof of better exposure or effects. Be careful with blends that bury the actual trans-resveratrol amount.7
FAQ
Is resveratrol a nootropic?
2Only weakly. Human evidence is more convincing for selected blood-flow and memory markers than for a reliable focus, productivity, or broad brain-performance effect.
What resveratrol dosage is most useful for comparison?
4A 14-week postmenopausal trial used 150 mg/day. This is a study-specific amount, not a universal dose target for every product or person.
How long does resveratrol take to work?
3In a small acute trial, testing followed a 45-minute absorption period and cognitive performance did not improve. That study does not establish an onset estimate or cycle.
Is trans-resveratrol different from resveratrol?
1Trans-resveratrol is the better-defined form most often emphasized on supplement labels and in human studies. If a product only says resveratrol blend, check whether the trans-resveratrol amount is stated.
Why does bioavailability matter?
7Resveratrol is rapidly metabolized after oral intake, and human free-resveratrol exposure varies across doses. Compare the stated amount and regard formulation, food, or absorption claims as product-specific unless that product has supporting human data.
References
- PubChem Compound Summary for CID 445154, resveratrol.
- Marx W, Kelly JT, Marshall S, Cutajar J, Annois B, et al. Effect of resveratrol supplementation on cognitive performance and mood in adults: a systematic literature review and meta-analysis of randomized controlled trials. Nutr Rev. 2018.
- Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, et al. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010.
- Evans HM, Howe PR, Wong RH. Effects of Resveratrol on Cognitive Performance, Mood and Cerebrovascular Function in Post-Menopausal Women; A 14-Week Randomised Placebo-Controlled Intervention Trial. Nutrients. 2017.
- Thaung Zaw JJ, Howe PR, Wong RH. Long-term effects of resveratrol on cognition, cerebrovascular function and cardio-metabolic markers in postmenopausal women: A 24-month randomised, double-blind, placebo-controlled, crossover study. Clin Nutr. 2021.
- Yadegar S, Mohammadi F, Yadegar A, Mohammadi Naeini A, Ayati A, et al. Effects and safety of resveratrol supplementation in older adults: A comprehensive systematic review. Phytother Res. 2024.
- Szymkowiak I, Marcinkowska J, Kucinska M, Regulski M, Murias M. Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data. Phytother Res. 2025.
- U.S. Food and Drug Administration. Structure/Function Claims.
- Wightman EL, Haskell-Ramsay CF, Reay JL, Williamson G, Dew T, Zhang W, Kennedy DO. The effects of chronic trans-resveratrol supplementation on aspects of cognitive function, mood, sleep, health and cerebral blood flow in healthy, young humans. Br J Nutr. 2015;114:1427-1437.
- Chow HH, Garland LL, Hsu CH, Vining DR, Chew WM, Miller JA, Perloff M, Crowell JA, Alberts DS. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila). 2010;3:1168-1175.
- Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010;70:9003-9011.
- Mankowski RT, You L, Buford TW, Leeuwenburgh C, Manini TM, Schneider S, Qiu P, Anton SD. Higher dose of resveratrol elevated cardiovascular disease risk biomarker levels in overweight older adults: A pilot study. Exp Gerontol. 2020;131:110821.